MFN Policy Impact on Pharmaceutical Launches in Nordic Countries
A report by GlobalData indicates a 35% decline in pharmaceutical launches in Europe following the introduction of the Most Favored Nation (MFN) policy in the US. The Nordic countries, particularly Sweden, have been disproportionately affected due to lower drug prices in the region, raising concerns about patient access to new medicines. The Danish and Swedish pharmaceutical associations have highlighted these issues.
Topics: MFN policy Nordic countries pharmaceutical industry pricing product launches